logo.jpg
Addex Reports Q1 2021 Financial Results and Provides Corporate Update
May 05, 2021 01:00 ET | Addex Therapeutics
Strong cash and cash equivalents position at March 31, 2021 of CHF25.2M ($26.7M)Completed $11.5M fundraising in January 2021Three clinical studies in neurology programs remain on track to start during...
logo.jpg
Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021
May 03, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, May 3, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex Increases Issued Share Capital to Create Treasury Shares
April 26, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum
April 26, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex to Present at the 20th Annual Needham Virtual Healthcare Conference
April 13, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, April 13, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
April 08, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, April 8, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
March 11, 2021 01:00 ET | Addex Therapeutics
Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) Balance sheet further strengthened by $11.5M fundraising on January 11, 2021Three clinical studies in neurology programs...
logo.jpg
Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021
March 09, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that...
logo.jpg
Addex to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, March 4, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
February 17, 2021 01:00 ET | Addex Therapeutics
Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...